BioStem Registers Resale of 3.57M Shares, Including 2.83M Anti-Dilution Overhang from May Placement
BSEM is trading near its 52-week low of $3.093 (9.9% above the low) on light trading volume (0.2× avg).
Summary
BioStem filed an S-1 to register resale of 3.57 million shares, including 2.83 million shares that could be issued under anti-dilution provisions from a May 2026 private placement. The anti-dilution overhang is newly disclosed and material at current prices.
Key Events · Financing and Capital Events · BSEM
-
Resale Shelf for 3.57M Shares
Registers resale of 746,269 shares from a May 2026 private placement at $3.35, plus up to 2,825,160 additional shares issuable under anti-dilution provisions if the company sells stock below $3.35 (floor $0.70).
-
Anti-Dilution Overhang
The 2.83M anti-dilution shares represent a newly disclosed overhang — if triggered, total resale shares would equal ~20% of the 17.8M shares outstanding, creating significant potential dilution.
-
Pricing Pressure
With the stock at $3.40, the anti-dilution trigger at $3.35 is near; any discounted financing could force issuance of millions of additional shares, compounding dilution.
-
No Proceeds to Company
All shares are being sold by the selling stockholder; BioStem receives no proceeds from the resale.
Analysis · BSEM · Life Sciences
This S-1 registers the resale of 746,269 shares sold in a May 2026 private placement at $3.35, but the bigger story is the registration of up to 2,825,160 additional shares that could be issued under anti-dilution protection if the company sells stock below $3.35 (floor $0.70). Those shares were not previously disclosed as a tradable overhang. With the stock at $3.40, the anti-dilution trigger is dangerously close, and the full 3.57M share shelf represents roughly 20% of the current outstanding — a significant potential dilution event if the selling stockholder moves to liquidate.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSEM was trading at $3.40 on OTC in the Life Sciences sector, with a market capitalization of approximately $55.6M. The 52-week trading range was $3.09 to $12.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.